

according to claim 5, which comprises said xylobiose or said xylooligosaccharide and a pharmaceutically acceptable carrier.

Claim 12. (Amended) The therapeutic agent of hepatic encephalopathy according to claim 9, which comprises said xylobiose or said xylooligosaccharide and a pharmaceutically acceptable carrier.

REMARKS

This Preliminary Amendment revises the multiple dependent claims 4, 8 and 12 to be single dependent claims in order to reduce the filing fee.

No new matter has been added.

Entry of this Amendment and favorable consideration of this application are respectfully requested.

Respectfully submitted,

MANELLI DENISON & SELTER, PLLC

By 

Paul E. White, Jr.

Reg. No. 32,011

Tel. No.: (202) 261-1050

Fax No.: (202) 887-0336

2000 M Street, N.W.
Seventh Floor
Washington, D.C. 20036-3307
(202) 261-1000

APPENDIX

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION:

Proposed Amendments To The Following Paragraphs Of The Specification Showing Deletions And Insertions.

IN THE CLAIMS:

Proposed Amendments To Claims 4, 8 and 12 Showing Deletions And Insertions.

Claim 4. (Amended) The blood ammonia lowering agent according to [any one of claims 1-3] claim 1, which comprises said xylobiose or said xylooligosaccharide and a pharmaceutically acceptable carrier.

Claim 8. (Amended) The therapeutic agent of hyperammonemia according to [any one of claims 5-7] claim 5, which comprises said xylobiose or said xylooligosaccharide and a pharmaceutically acceptable carrier.

Claim 12. (Amended) The therapeutic agent of hepatic encephalopathy according to [any one of claims 9-11] claim 9, which comprises said xylobiose or said xylooligosaccharide and a pharmaceutically acceptable carrier.